Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 16/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22124853 | 0.94 | TTK (0.46) | TTKBRAFPTK6ABL1BCR | |
| SCHEMBL22124906 | 0.94 | TTK (0.46) | TTKBRAFPTK6ABL1BCR | |
| SCHEMBL22124744 | 0.93 | TTK (0.45) | TTKBRAFPTK6ABL1BCR | |
| SCHEMBL22124721 | 0.93 | TTK (0.45) | TTKBRAFPTK6ABL1BCR | |
| SCHEMBL22124802 | 0.92 | TTK (0.45) | TTKBRAFPTK6ABL1BCR | |
| SCHEMBL22124934 | 0.92 | TTK (0.45) | TTKBRAFPTK6ABL1BCR | |
| Hydrochloric Acid SCHEMBL30171610 | 0.92 | TTK (0.45) | TTKBRAFPTK6ABL1BCR | |
| SCHEMBL22124524 | 0.92 | TTK (0.44) | TTKBRAFPTK6ABL1BCR | |
| SCHEMBL22124781 | 0.91 | TTK (0.44) | TTKBRAFPTK6ABL1BCR | |
| SCHEMBL22124919 | 0.91 | TTK (0.45) | TTKBRAFPTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | claimed |
| EP-3898630-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126954-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898630-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126954-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | TTK 4573/4885BRAF 955/4885PTK6 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.